IRRAS publishes prospectus

2023-10-16

On 13 October 2023, IRRAS AB (publ) ("IRRAS" or the "Company") (Nasdaq Stockholm: IRRAS) announced that the extraordinary general meeting on the same day had resolved to increase the Company’s share capital by a maximum of 10,147,945.20 through an issue of a maximum of 338,264,840 ordinary shares against payment by way of set-off against IR Holdings’ short term loan financing of SEK 60,000,000 plus accrued interest of SEK 887,671. The subscription price was SEK 0.18 per ordinary share. Ahead of the admission of the new shares to trading on Nasdaq Stockholm the Company has prepared a prospectus that has been approved and registered by the Swedish Financial Supervisory Authority. The prospectus is available on IRRAS’ website, www.irras.com, and will be available on SFSA's website, www.fi.se.

The first day of trading of the new shares on Nasdaq Stockholm is expected to be on or around 19 October 2023.

For more information, please contact:

Will Martin
President and Chief Executive Officer
ir@irras.com

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).